INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY
发明人:
Geun Joong KIM,Jin-Young LEE,Sa-Young MIN,Sung-Hwan YOU,Jung-Joon MIN
申请号：
US15023245
公开号：
US20170354738A1
申请日:
2015.10.21
申请国别(地区):
US
年份:
2017
代理人:
摘要：
A drug delivery system composition includes Corynebacterium sp. bacteria or Corynebacterium sp. bacteria-derived minicells. The drug delivery system composition is safer for use in human bodies than other bacteria (for example, Escherichia coli (E. coli), Salmonella sp. bacteria, Bacillus sp. bacteria, or the like), or other bacteria-derived drug delivery system. When an anti-cancer drug protein expression construct (protein expression recombinant vector or the like) is included, over-expression of an anti-cancer drug protein, effective protein expression control in vivo, and targeting technique using expression of targeting factor. The drug delivery system composition enables stable drug delivery in vivo, thereby maximizing anti-cancer therapeutic effects.
